EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›LMED

LMED

LataMed AI Corp.

Next earnings ≈ Oct 20, 2026 · est. from filing cadence

Hold
$3.40▲ +566.67%
over 1Y
L $0.37Yahoo FinanceH $3.40
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+7.6%
1M+58.9%
3M+178.7%
YTD+423.0%
1Y+566.7%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
C
Valuation
Fair value
Filings
Flagged
Hold
Conviction
Horizon
Medium (3–12mo)

High return on equity (32.9%).

Revenue (FY2025) $0.00 · FY2025

LataMed AI Corp. shows $0.00 in FY2025 revenue, and 32.9% ROE.

Financials · annual, by fiscal year

Line itemFY23FY24FY25
Revenue$0.00$0.00$0.00
Gross profit———
Operating income-$829K-$3.30M-$172K
Net income-$1.73M-$3.26M-$207K
Diluted EPS-$0.02-$0.11—
Net margin———

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash$0.00

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+91.7%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — late filing notice (2026-05-15). Worth a closer look.
  1. 10-Q Quarterly report2026-05-20
  2. NT 10-Q Late filing notice2026-05-15
  3. 8-K Charter / bylaws change2026-05-08
  4. 8-K Charter / bylaws change2026-05-04
  5. 10-K/A Restated periodic report2026-05-04
  6. 10-K Annual report2026-04-16
  7. 8-K Material agreement2026-04-13
  8. 8-K Officer / director change2026-04-08
  9. NT 10-K Late filing notice2026-03-31

Recent filings

all on EDGAR ↗
10-QPeriod ending 2026-03-312026-05-20open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-062026-05-08open ↗8-KPeriod ending 2026-04-282026-05-04open ↗10-K/APeriod ending 2025-12-312026-05-04open ↗10-KPeriod ending 2025-12-312026-04-16open ↗8-KPeriod ending 2026-02-172026-04-13open ↗8-KPeriod ending 2026-03-312026-04-08open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-02-172026-02-25open ↗10-QPeriod ending 2025-09-302025-11-14open ↗10-QPeriod ending 2025-06-302025-08-14open ↗

Quality score

C
ValueGrowthProfitHealthMom.
Value—
GrowthA+
Profitability—
Financial healthF
Momentum—
  • ✗Profitable (positive net income)
  • ✓Liabilities below 2× equity
Revenue
$0.00
Net margin
—
ROE
—
P/E
—

SEC fundamentals · FY 2025

■ revenue · ■ net income, by fiscal year

Revenue$0.00
Net income-$207K+93.6%
Operating income-$172K+94.8%
Diluted EPS-$0.11-450.0%
Cash & equivalents$0.00
Total assets$0.00
Total liabilities$631K+10.0%
Stockholders' equity-$631K-10.0%
L/E: -1.00x

Frequently asked

Is LataMed AI Corp. (LMED) a buy?
LMED currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (32.9%).
What is LataMed AI Corp.'s quality score?
LMED scores 57.5/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001477960, latest 10-Q filed 2026-05-20) · as of 6/22/2026, 9:51:35 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score58 vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5